Production of genetically inactivated SIVsmmPBj14 viruslike particles for use as a potential vaccine.

Important note: Information in this article was accurate in 1993. The state of the art may have changed since the publication date.

Production of genetically inactivated SIVsmmPBj14 viruslike particles for use as a potential vaccine.

Symp Nonhum Primate Models AIDS. 1992 Nov 17-20;10:abstract no. 114. Unique Identifier : AIDSLINE PRIM10/93200957
Deschamps M; Horth M; Kummert S; Gelderblom H; Thiriart C; Bruck C; Burny A; Laboratory of Biological Chemistry, Free University of Brussels,; Rhode-St-Genese, Belgium.

Abstract: We have recently established a stable Vero cell line that produces genetically inactivated SIVsmPBj1.9 (molecular clone of SIVsmmPBj14) viral particles that are very similar to the native virus and that are non-infectious in vitro. The SIVsmmPBj1.9 provirus deleted of its 3'LTR, was expressed in Vero cells in stable transfection experiments using the 5'LTR promoter. The structure, maturation and morphogenesis of the genetically inactivated SIVsmmPBj14 viruslike particles, present in cell supernatants, was studied by ELISA assay, Western Blot analysis, RIPA assay and electron microscopy. Gel exclusion chromatography on cell supernatants show that our Vero cell clone produces over 90% of viruslike particles versus free Ag. Both cell-free and co-culture infectivity tests of the genetically inactivated SIVsmmPBj1.9 viruslike particles show that the viruslike particles remain non-infectious in vitro for a period of two months. In vivo studies in pig-tailed-macaques will allow a fast evaluation of the efficiency of our genetically inactivated SIVsmmPBj1.9 viruslike particles as a vaccine due to the very strong SAIDS pathogenicity induced in pig-tailed macaques upon SIVsmmPBj14 infection.

Keywords: Animal Blotting, Western Chromatography, Gel Enzyme-Linked Immunosorbent Assay Macaca nemestrina Proviruses/GENETICS/IMMUNOLOGY Repetitive Sequences, Nucleic Acid Sequence Deletion Simian Acquired Immunodeficiency Syndrome/*IMMUNOLOGY/PREVENTION & CONTROL SIV/GENETICS/*IMMUNOLOGY Transfection Vaccines, Inactivated/*GENETICS Vero Cells Viral Vaccines/*GENETICS ABSTRACT
930630
M9361063

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1993. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1993. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .